Dawn I Velligan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6325786/publications.pdf

Version: 2024-02-01

		87843	62565
118	6,706 citations	38	80
papers	citations	h-index	g-index
122	122	122	6827
122	122	122	0027
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Beyond hypofrontality: A quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Human Brain Mapping, 2005, 25, 60-69.	1.9	547
2	Self-report measures of medication adherence behavior: recommendations on optimal use. Translational Behavioral Medicine, 2015, 5, 470-482.	1.2	524
3	The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research, 1997, 25, 21-31.	1.1	307
4	Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature. Schizophrenia Bulletin, 2005, 32, 724-742.	2.3	239
5	The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. Journal of Clinical Psychiatry, 2009, 70 Suppl 4, 1-46; quiz 47-8.	1.1	235
6	Do Specific Neurocognitive Deficits Predict Specific Domains of Community Function in Schizophrenia?. Journal of Nervous and Mental Disease, 2000, 188, 518-524.	0.5	220
7	Performance-Based Measures of Functional Skills: Usefulness in Clinical Treatment Studies. Schizophrenia Bulletin, 2007, 33, 1138-1148.	2.3	218
8	The Neurocognitive Signature of Psychotic Bipolar Disorder. Biological Psychiatry, 2007, 62, 910-916.	0.7	210
9	Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications. Psychiatric Services, 2007, 58, 1187-1192.	1.1	209
10	Randomized Controlled Trial of the Use of Compensatory Strategies to Enhance Adaptive Functioning in Outpatients With Schizophrenia. American Journal of Psychiatry, 2000, 157, 1317-1328.	4.0	203
11	Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Preference and Adherence, 2017, Volume 11, 449-468.	0.8	201
12	Cognitive Functioning in Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 361-372.	1.1	191
13	Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophrenia Research, 2002, 53, 239-248.	1.1	172
14	Cognitive Rehabilitation for Schizophrenia and the Putative Role of Motivation and Expectancies. Schizophrenia Bulletin, 2005, 32, 474-485.	2.3	162
15	Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis. Bipolar Disorders, 2006, 8, 117-123.	1.1	154
16	Strategies for Addressing Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations From the Expert Consensus Guidelines. Journal of Psychiatric Practice, 2010, 16, 306-324.	0.3	147
17	The Use of Individually Tailored Environmental Supports to Improve Medication Adherence and Outcomes in Schizophrenia. Schizophrenia Bulletin, 2007, 34, 483-493.	2.3	132
18	Executive-frontal lobe cognitive dysfunction in schizophrenia: A symptom subtype analysis. Psychiatry Research, 1998, 79, 139-149.	1.7	129

#	Article	IF	Citations
19	Measurement of psychiatric treatment adherence. Journal of Psychosomatic Research, 2010, 69, 591-599.	1.2	125
20	Assessment of Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations from the Expert Consensus Guidelines. Journal of Psychiatric Practice, 2010, 16, 34-45.	0.3	103
21	Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Research, 1999, 86, 131-142.	1.7	102
22	Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function. Psychiatry Research, 2002, 113, 227-236.	1.7	102
23	A Randomized Single-Blind Pilot Study of Compensatory Strategies in Schizophrenia Outpatients. Schizophrenia Bulletin, 2002, 28, 283-292.	2.3	101
24	Brief Psychiatric Rating Scale Expanded Version: How do new items affect factor structure?. Psychiatry Research, 2005, 135, 217-228.	1.7	94
25	Psychopharmacology: Perspectives on Medication Adherence and Atypical Antipsychotic Medications. Psychiatric Services, 2003, 54, 665-667.	1.1	92
26	Rehab Rounds: Two Case Studies of Cognitive Adaptation Training for Outpatients With Schizophrenia. Psychiatric Services, 2000, 51, 25-29.	1.1	78
27	The Texas Medication Algorithm Project: Clinical Results for Schizophrenia. Schizophrenia Bulletin, 2004, 30, 627-647.	2.3	77
28	A Randomized Trial Comparing In Person and Electronic Interventions for Improving Adherence to Oral Medications in Schizophrenia. Schizophrenia Bulletin, 2013, 39, 999-1007.	2.3	70
29	The Effectiveness of Quetiapine Versus Conventional Antipsychotics in Improving Cognitive and Functional Outcomes in Standard Treatment Settings. Journal of Clinical Psychiatry, 2003, 64, 524-531.	1.1	70
30	A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia. Schizophrenia Research, 2015, 165, 175-180.	1.1	65
31	A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophrenia Research, 2004, 71, 273-283.	1.1	62
32	Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophrenia Research, 2008, 102, 312-319.	1.1	61
33	Conceptualization and treatment of negative symptoms in schizophrenia. World Journal of Psychiatry, 2015, 5, 352.	1.3	58
34	Deconstructing processing speed deficits in schizophrenia: Application of a parametric digit symbol coding test. Schizophrenia Research, 2010, 118, 6-11.	1.1	54
35	The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). Psychiatry Research, 2007, 151, 55-66.	1.7	49
36	Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Research, 2009, 169, 97-100.	1.7	46

#	Article	IF	Citations
37	Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. International Journal of Neuropsychopharmacology, 2014, 17, 1139-1148.	1.0	46
38	Use of Environmental Supports Among Patients With Schizophrenia. Psychiatric Services, 2006, 57, 219-224.	1.1	41
39	Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. European Neuropsychopharmacology, 2018, 28, 369-380.	0.3	41
40	A homeâ€delivered intervention for depressed, cognitively impaired, disabled elders. International Journal of Geriatric Psychiatry, 2011, 26, 256-262.	1.3	34
41	Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophrenia Research, 2012, 134, 59-64.	1.1	34
42	Compensatory Interventions for Cognitive Impairments in Psychosis: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2020, 46, 869-883.	2.3	33
43	Dissociable mechanisms for memory impairment in bipolar disorder and schizophrenia. Psychological Medicine, 2006, 36, 1085-1095.	2.7	30
44	A social cognitive approach to emotional intensity judgment deficits in schizophrenia. Schizophrenia Research, 2007, 94, 245-252.	1.1	30
45	Outcomes of Medicaid Beneficiaries With Schizophrenia Receiving Clozapine Only or Antipsychotic Combinations. Psychiatric Services, 2015, 66, 127-133.	1.1	30
46	The short-term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia. Psychiatry Research, 2009, 168, 94-101.	1.7	29
47	Methodological Challenges in Psychiatric Treatment Adherence Research. Clinical Schizophrenia and Related Psychoses, 2010, 4, 74-91.	1.4	29
48	Is cognitive adaptation training (CAT) compensatory, restorative, or both?. Schizophrenia Research, 2015, 166, 290-296.	1.1	28
49	Cognitive Adaptation Training: Establishing Environmental Supports to Bypass Cognitive Deficits and Improve Functional Outcomes. American Journal of Psychiatric Rehabilitation, 2008, 11, 164-180.	0.7	27
50	Can Social Functioning in Schizophrenia Be Improved through Targeted Social Cognitive Intervention?. Rehabilitation Research and Practice, 2012, 2012, 1-8.	0.5	27
51	A comparison of instrument sensitivity to negative symptom change. Psychiatry Research, 1996, 63, 67-75.	1.7	25
52	Rehabilitation and Recovery in Schizophrenia. Psychiatric Clinics of North America, 2007, 30, 535-548.	0.7	25
53	Integrated Psychosocial Treatment for Negative Symptoms. American Journal of Psychiatric Rehabilitation, 2014, 17, 1-19.	0.7	24
54	The Cultural Adaptability of Intermediate Measures of Functional Outcome in Schizophrenia*. Schizophrenia Bulletin, 2012, 38, 630-641.	2.3	23

#	Article	IF	Citations
55	Cognitive adaptation training for outpatients with schizophrenia. Journal of Clinical Psychology, 2009, 65, 842-853.	1.0	22
56	A Randomized Controlled Trial Comparing Cognitive Behavior Therapy, Cognitive Adaptation Training, Their Combination and Treatment as Usual in Chronic Schizophrenia. Schizophrenia Bulletin, 2015, 41, 597-603.	2.3	22
57	Caregiver Burdens Associated With Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes, and Perceptions. Frontiers in Psychiatry, 2019, 10, 584.	1.3	22
58	Improving functional outcomes for schizophrenia patients in the Netherlands using Cognitive Adaptation Training as a nursing intervention — A pilot study. Schizophrenia Research, 2014, 158, 120-125.	1.1	21
59	The Reliability and Validity of the MATRICS Functional Assessment Battery. Schizophrenia Bulletin, 2014, 40, 1047-1052.	2.3	21
60	Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia. Schizophrenia Research and Treatment, 2012, 2012, 1-3.	0.7	18
61	Multimodal Cognitive Therapy: Combining Treatments That Bypass Cognitive Deficits and Deal With Reasoning and Appraisal Biases. Schizophrenia Bulletin, 2009, 35, 884-893.	2.3	16
62	A comparison of compensatory and restorative cognitive interventions in early psychosis. Schizophrenia Research: Cognition, 2020, 19, 100157.	0.7	16
63	Barriers to, and Strategies for, Starting a Long Acting Injection Clinic in a Community Mental Health Center. Community Mental Health Journal, 2011, 47, 654-659.	1.1	15
64	Testing a modification of cognitive adaptation training: Streamlining the model for broader implementation. Schizophrenia Research, 2014, 156, 46-50.	1.1	15
65	Effectiveness and cost-effectiveness of cognitive adaptation training as a nursing intervention in long-term residential patients with severe mental illness: study protocol for a randomized controlled trial. Trials, 2015, 16, 49.	0.7	15
66	What Patients With Severe Mental Illness Transitioning From Hospital to Community Have to Say About Care and Shared Decision-Making. Issues in Mental Health Nursing, 2016, 37, 400-405.	0.6	15
67	Assessment of adherence to oral antipsychotic medications: What has changed over the past decade?. Schizophrenia Research, 2020, 215, 17-24.	1.1	15
68	In-office, in-home, and telehealth cognitive processing therapy for posttraumatic stress disorder in veterans: a randomized clinical trial. BMC Psychiatry, 2022, 22, 41.	1.1	15
69	A qualitative assessment of cross-cultural adaptation of intermediate measures for schizophrenia in multisite international studies. Psychiatry Research, 2013, 206, 166-172.	1.7	14
70	Feasibility and acceptability of cognitive adaptation training for firstâ€episode psychosis. Microbial Biotechnology, 2016, 10, 476-484.	0.9	14
71	A pilot study of a family cognitive adaptation training guide for individuals with schizophrenia Psychiatric Rehabilitation Journal, 2018, 41, 109-117.	0.8	14
72	X-Aptamer Technology Identifies C4A and ApoB in Blood as Potential Markers for Schizophrenia. Molecular Neuropsychiatry, 2019, 5, 52-59.	3.0	14

#	Article	IF	Citations
73	<p>Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey</p> . Patient Preference and Adherence, 2020, Volume 14, 2043-2054.	0.8	14
74	Enhancing patient adherence: introducing smart pill devices. Therapeutic Delivery, 2014, 5, 611-613.	1.2	13
75	The welcome basket revisited: Testing the feasibility of a brief peer support intervention to facilitate transition from hospital to community Psychiatric Rehabilitation Journal, 2016, 39, 335-342.	0.8	13
76	Improving vocational outcomes in first-episode psychosis by addressing cognitive impairments using Cognitive Adaptation Training. Work, 2017, 56, 581-589.	0.6	13
77	Issues and developments related to assessing function in serious mental illness. Dialogues in Clinical Neuroscience, 2016, 18, 135-144.	1.8	13
78	Facilitating Recovery of Daily Functioning in People With a Severe Mental Illness Who Need Longer-Term Intensive Psychiatric Services: Results From a Cluster Randomized Controlled Trial on Cognitive Adaptation Training Delivered by Nurses. Schizophrenia Bulletin, 2020, 46, 1259-1268.	2.3	12
79	Motivating Persons with Schizophrenia Spectrum Disorders to Exercise: Rationale and Design. Clinical Schizophrenia and Related Psychoses, 2009, 3, 111-116.	1.4	12
80	Medication adherence in schizophrenia. Drug Discovery Today: Therapeutic Strategies, 2011, 8, 11-15.	0.5	10
81	Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine. Journal of Psychiatric Research, 2017, 90, 26-30.	1.5	10
82	Addressing chronic pain with Focused Acceptance and Commitment Therapy in integrated primary care: findings from a mixed methods pilot randomized controlled trial., 2022, 23, 77.		9
83	Cognitive adaptation training: The use of compensatory strategies for inpatients and outpatients with schizophrenia. Schizophrenia Research, 1997, 24, 229.	1.1	8
84	Interrater Reliability of Using Brief Standardized Outcome Measures in a Community Mental Health Setting. Psychiatric Services, 2011, 62, 558-560.	1.1	8
85	Design of a clinical effectiveness trial of in-home cognitive processing therapy for combat-related PTSD. Contemporary Clinical Trials, 2018, 73, 27-35.	0.8	8
86	International assessment of functional skills in people with schizophrenia. Innovations in Clinical Neuroscience, 2011, 8, 15-8.	0.1	8
87	A Case Control Study of the Implementation of Change Model Versus Passive Dissemination of Practice Guidelines for Compliance in Monitoring for Metabolic Syndrome. Community Mental Health Journal, 2013, 49, 141-149.	1.1	7
88	Improving Functional Outcome Using Compensatory Strategies in Comorbid Intellectual Disability and Psychosis: A Case Study. American Journal of Psychiatric Rehabilitation, 2013, 16, 50-65.	0.7	7
89	Engagement-focused care during transitions from inpatient and emergency psychiatric facilities. Patient Preference and Adherence, 2017, Volume 11, 919-928.	0.8	7
90	Randomized trial of a brief peer support intervention for individuals with schizophrenia transitioning from hospital to community. Schizophrenia Research, 2021, 231, 214-220.	1.1	7

#	Article	IF	Citations
91	Cognitive Behavior Therapy for Psychosis: Where Have We Been and Where Are We Going?. Schizophrenia Bulletin, 2009, 35, 857-858.	2.3	6
92	Rationale and design of a pilot study examining Acceptance and Commitment Therapy for persistent pain in an integrated primary care clinic. Contemporary Clinical Trials, 2018, 66, 28-35.	0.8	6
93	Cognitive Adaptation Training Provided to Chronically Hospitalized Patients with Schizophrenia in The Netherlands: Two Case Reports. Case Reports in Psychiatry, 2012, 2012, 1-4.	0.2	5
94	The Daily Activity Report (DAR) a Novel Measure of Functional Outcome for Serious Mental Illness. Schizophrenia Bulletin, 2016, 42, 579-587.	2.3	5
95	Public-Academic Partnerships: Research in Community Mental Health Settings: A Practicum Experience for Researchers. Psychiatric Services, 2008, 59, 1246-1248.	1.1	4
96	Following AACP Guidelines for Transitions in Care: The Transitional Care Clinic. Psychiatric Services, 2016, 67, 259-261.	1.1	4
97	A Program to Increase the Appropriate Use of Long-Acting Injectable Antipsychotic Medications in Community Settings. Psychiatric Services, 2021, 72, 1012-1017.	1.1	4
98	Practical strategies for improving adherence to medication and outcomes. World Psychiatry, 2013, 12, 233-234.	4.8	3
99	A case control study of association between cognition and functional capacity in schizophrenia. Schizophrenia Research, 2015, 169, 165-168.	1.1	3
100	Mental Health Care Provider's Perspectives Toward Adopting a Novel Technology to Improve Medication Adherence. Psychiatric Research and Clinical Practice, 2022, 4, 61-70.	1.3	3
101	Patient and Provider Perspectives on Medication Non-adherence Among Patients with Depression and/or Diabetes in Diverse Community Settings – A Qualitative Analysis. Patient Preference and Adherence, 0, Volume 16, 1581-1594.	0.8	3
102	Development and Feasibility Exploration of a Combined Compensatory and Restorative Approach to Addressing Cognitive Challenges in Early Intervention Psychosis. Cognitive and Behavioral Practice, 2020, 27, 454-469.	0.9	2
103	Sensitivity To Negative Symptom Change: SANS, NSA, and BPRS-R. Neuropsychopharmacology, 1994, 11, 270-270.	2.8	1
104	Treating the cognitive deficits of schizophrenia. Current Psychosis & Therapeutics Reports, 2004, 2, 73-77.	0.1	1
105	Interventions to improve oral medication adherence in psychosis: the role of adherence measurement. Neuropsychiatry, 2011, 1, 361-369.	0.4	1
106	The Use of Access Groups for Engagement in Community Mental Health Post Hospitalization. Community Mental Health Journal, 2018, 54, 533-539.	1.1	1
107	S118. THE ASSESSMENT OF ADHERENCE TO ORAL ANTIPSYCHOTIC MEDICATIONS: WHAT HAS CHANGED IN THE PAST DECADE?. Schizophrenia Bulletin, 2019, 45, S351-S352.	2.3	1
108	T224. TESTING THE EFFECTIVENESS OF A BRIEF, PEER SUPPORT INTERVENTION TO FACILITATE TRANSITION FROM PSYCHIATRIC HOSPITALIZATION FOR A SCHIZOPHRENIA SPECTRUM POPULATION. Schizophrenia Bulletin, 2020, 46, S318-S318.	2.3	1

#	Article	IF	CITATIONS
109	Prescriber Attitudes, Experiences, and Proclivities Toward Digital Medicine and How They Influence Adoption of Digital Medicine Platforms. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 3715-3726.	1.0	1
110	Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials. Expert Review of Clinical Pharmacology, 2016, 9, 591-604.	1.3	0
111	S203. COMPENSATORY COGNITIVE APPROACHES TO IMPROVING FUNCTIONING IN PSYCHOSIS: SYSTEMATIC REVIEW AND META-ANALYSIS. Schizophrenia Bulletin, 2018, 44, S404-S405.	2.3	0
112	19.1 FROM CLINICAL TRIAL TO THE CLINIC: OPTIMIZING COGNITIVE ADAPTATION TRAINING FOR CASE MANAGEMENT TEAMS. Schizophrenia Bulletin, 2018, 44, S31-S31.	2.3	0
113	Improving Self-Care, Attention/Memory, Motivation and Social Functioning. , 0, , 89-104.		0
114	19. THE IMPLEMENTATION OF COGNITIVE ADAPTATION TRAINING (CAT) ACROSS COUNTRIES. Schizophrenia Bulletin, 2018, 44, S30-S31.	2.3	0
115	26.1 MULTI-LEVEL FACILITATION OF LONG-ACTING ANTIPSYCHOTIC USE/MAP IN ENGAGEMENT FOCUSED CARE. Schizophrenia Bulletin, 2019, 45, S131-S132.	2.3	0
116	18.1 ENVIRONMENTAL SUPPORTS AND THE KITCHEN SINK: IMPROVING NEGATIVE SYMPTOMS IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S117-S118.	2.3	0
117	T236. A PROGRAM TO INCREASE THE APPROPRIATE USE OF LONG-ACTING ANTIPSYCHOTIC MEDICATIONS IN COMMUNITY SETTINGS. Schizophrenia Bulletin, 2020, 46, S322-S323.	2.3	O
118	The effect of objectively collected medication adherence information on bipolar I and major depressive disorder treatment decisions: A randomized case vignette study of psychiatric clinicians. Journal of Affective Disorders Reports, 2022, 9, 100344.	0.9	0